Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.66 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5270011 | 0.92 | AKR1C3 (0.74) | AKR1C3AKR1C2PTGS2TUBB1PTGS1 | |
| SCHEMBL5268342 | 0.84 | AKR1C3 (0.78) | AKR1C3AKR1C2PTGS2TUBB1PTGS1 | |
| SCHEMBL11037919 | 0.81 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2TUBB1PTGS1 | |
| SCHEMBL29481380 | 0.81 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2TUBB1PTGS1 | |
| Acetic Acid SCHEMBL11761270 | 0.78 | AKR1C3 (0.93) | AKR1C3AKR1C2PTGS2TUBB1PTGS1 | |
| SCHEMBL7876338 | 0.77 | PTGS2 (0.70) | AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL5266834 | 0.77 | AKR1C3 (0.73) | AKR1C3AKR1C2PTGS2TUBB1PTGS1 | |
| SCHEMBL5267237 | 0.77 | AKR1C3 (0.73) | AKR1C3AKR1C2PTGS2TUBB1PTGS1 | |
| SCHEMBL5267004 | 0.76 | AKR1C3 (0.69) | AKR1C3AKR1C2PTGS2TUBB1PTGS1 | |
| SCHEMBL5266160 | 0.76 | AKR1C3 (0.72) | AKR1C3AKR1C2PTGS2TUBB1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050031537-A1 | Are screened for Cyclooxygenase protein independent of therapeutic activity; anticarcinogenic agents; Alzheimer's disease and atherosclerosis | CORNELL RESEARCH FOUNDATION, INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050031537-A1 | Are screened for Cyclooxygenase protein independent of therapeutic activity; anticarcinogenic agents; Alzheimer's disease and atherosclerosis | PTGS1, PTGES2, PTGS2 | AKR1C3 1802/4885AKR1C2 1167/4885PTGS2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.